Summary
Gilead Sciences, Inc. (GILD) filed an 8-K report on October 22, 2007, primarily announcing the appointment of Caroline Dorsa as its new Chief Financial Officer (CFO). Ms. Dorsa's appointment, effective November 5, 2007, marks a significant addition to the executive team, bringing extensive financial experience from her previous roles at Avaya, Inc. and notably, a 20-year tenure at Merck & Co., Inc. where she held significant responsibilities including Treasurer, tax, portfolio management, and investor relations. This filing details Ms. Dorsa's comprehensive compensation package, including a base salary of $500,000, a target bonus, a $250,000 signing bonus, and significant equity awards in the form of stock options and performance-based restricted stock units. The company has also provided a substantial relocation package and outlined repayment obligations for the signing bonus and relocation assistance under certain termination conditions within the first two years of employment. This executive transition is a key event for investors to monitor for its potential impact on financial strategy and execution.
Key Highlights
- 1Gilead Sciences appointed Caroline Dorsa as Chief Financial Officer, effective November 5, 2007.
- 2Ms. Dorsa brings 20 years of experience from Merck & Co., Inc., where she served as Vice President and Treasurer.
- 3John F. Milligan, Ph.D. (COO) will no longer serve as interim CFO but will continue as COO.
- 4Ms. Dorsa's compensation includes a $500,000 annual base salary and a target bonus of 40% of base salary.
- 5She will receive a $250,000 signing bonus.
- 6Equity awards include options for 100,000 shares and 24,000 performance-based restricted stock units.
- 7A significant relocation package and specific repayment terms for the signing bonus and relocation assistance are detailed.